Enhanced noscapine delivery using estrogen-receptor-targeted nanoparticles for breast cancer therapy

Anti-Cancer Drugs

Volumn 25, Issue 6, 2014, Pages 704-716

  Madan, Jitender ^a,b   Gundala, Sushma R ^a   Kasetti, Yoganjaneyulu ^c   Bharatam, Prasad V ^c   Aneja, Ritu ^a   Katyal, Anju ^d   Jain, Upendra K ^b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Chandigarh College of Pharmacy   (India)

^c NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^d UNIVERSITY OF DELHI   (India)

Author keywords

Breast cancer; Cytotoxicity; Estrone; Gelatin nanoparticles in silico docking; Noscapine

Indexed keywords

ACETONE; ALCOHOL; ALKALOID DERIVATIVE; DRUG CARRIER; ESTROGEN RECEPTOR; ESTRONE; ESTRONE GELATIN NANOPARTICLE; GELATIN; NANOPARTICLE; NOSCAPINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTITUSSIVE AGENT;

ALPHA HELIX; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CIRCULAR DICHROISM; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; IC 50; MCF 7 CELL LINE; MOLECULAR MODEL; NANOENCAPSULATION; NUDE MOUSE; PARTICLE SIZE; PH; PRIORITY JOURNAL; SURFACE PROPERTY; BREAST NEOPLASMS; CHEMISTRY; FEMALE; IC50; METABOLISM; MOLECULARLY TARGETED THERAPY; PROTEIN SECONDARY STRUCTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTITUSSIVE AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ESTRONE; FEMALE; GELATIN; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NOSCAPINE; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, ESTROGEN;

EID: 84901608239     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0000000000000098     Document Type: Article

References (41)

1. Chandra R, Madan J, Singh P, Chandra A, Kumar P, Tomar V, Dass SK. Implications of nanoscale based drug delivery systems in delivery and targeting tubulin binding agent. Curr Drug Metab 2012; 13:1476-1483.
2. Liu CW, Lin WJ. Polymeric nanoparticles conjugate a novel heptapeptide as an epidermal growth factor receptor-Active targeting ligand for doxorubicin. Int J Nanomedicine 2012; 7:4749-4767.
3. Olsson B, Bolme P, Dahlstrom B, Marcus C. Excretion of noscapine in human breast milk. Eur J Clin Pharmacol 1986; 30:213-215. (Pubitemid 16166072)
4. Aneja R, Dhiman N, Idnani J, Awasthi A, Arora SK, Chandra R, Joshi HC. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent. Cancer Chemother Pharmacol 2007; 60:831-839. (Pubitemid 47389389)
5. Madan J, Dhiman N, Parmar VK, Sardana S, Bharatam PV, Aneja R, et al. Inclusion complexes of noscapine in beta-cyclodextrin offer better solubility and improved pharmacokinetics. Cancer Chemother Pharmacol 2010; 65:537-548.
6. Madan J, Pandey RS, Jain V, Katare OP, Chandra R, Katyal A. Poly(ethylene)-glycol conjugated solid lipid nanoparticles of noscapine improve biological half-life, brain delivery and efficacy in glioblastoma cells. Nanomedicine 2013; 9:492-503.
7. Madan J, Baruah B, Nagaraju M, Abdalla MO, Yates C, Turner T, et al. Molecular cycloencapsulation augments solubility and improves therapeutic index of brominated noscapine in prostate cancer cells. Mol Pharm 2012; 9:1470-1480.
8. Madan J, Dhiman N, Sardana S, Aneja R, Chandra R, Katyal A. Longcirculating poly(ethylene glycol)-grafted gelatin nanoparticles customized for intracellular delivery of noscapine: Preparation, in-vitro characterization, structure elucidation, pharmacokinetics, and cytotoxicity analyses. Anticancer Drugs 2011; 22:543-555.
9. Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Blood Substit Immobil Biotechnol 2010; 38:230-249.
10. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005; 19:1951-1959. (Pubitemid 41124194)
11. Santner SJ, Ohlsson-Wilhelm B, Santen RJ. Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. Int J Cancer 1993; 54:119-124. (Pubitemid 23137008)
12. Billich A, Nussbaumer P, Lehr P. Stimulation of MCF-7 breast cancer cell proliferation by estrone sulfate and dehydroepiandrosterone sulfate: Inhibition by novel non-steroidal steroid sulfatase inhibitors. J Steroid Biochem Mol Biol 2000; 73:225-235.
13. MacCarthy-Morrogh L, Townsend PA, Purohit A, Hejaz HAM, Potter BVL, Reed MJ, Packham G. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 2000; 60:5441-5450.
14. Shcherbakov VM, Devichenskii VM, Vorontsov EA, Kuznetsov SL, Kriukov LN. Synthesis and antiproliferative activity of a novel N-Acyl derivative of doxorubicin. Bioorg Khim 1999; 25:226-229.
15. Paliwal SR, Paliwal R, Agrawal GP, Vyas SP. Targeted breast cancer nanotherapeutics: Options and opportunities with estrogen receptors. Crit Rev Ther Drug Carrier Syst 2012; 29:421-446.
16. Paliwal SR, Paliwal R, Pal HC, Saxena AK, Sharma PR, Gupta PN, et al. Estrogen-Anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Mol Pharm 2012; 9:176-181.
17. Paliwal SR, Paliwal R, Mishra N, Mehta A, Vyas SP. A novel cancer targeting approach based on estrone anchored stealth liposome for site-specific breast cancer therapy. Curr Cancer Drug Targets 2010; 10:343-353.
18. Ghafouri-Fard S, Abdollahi DZ, Omrani M, Azizi F. shRNA mediated RHOXF1 silencing influences expression of BCL2 but not CASP8 in MCF-7 and MDAMB-231 cell lines. Asian Pac J Cancer Prev 2012; 13:5865-5869.
19. Li Z, Wang S, Lee NA, Allan RD, Kennedy IR. Development of a solid-phase extraction-enzyme linked immunosorbent assay method for the determination of estrone in water. Anal Chim Acta 2004; 503: 171-177. (Pubitemid 38032936)
20. Basu A, Shrivastav TG, Maitra SK. A direct antigen heterologous enzyme immunoassay for measuring progesterone in serum without using displacer. Steroids 2006; 71:222-230. (Pubitemid 43208959)
21. Fields R. The measurement of amino groups in proteins and peptides. Biochem J 1971; 124:581-590.
22. Azarmi S, Huang Y, Chen H, Mcquarrie S, Abrams D, Roa W, et al. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharm Sci 2006; 9:124-132.
23. Verma AK, Sachin K, Saxena A, Bohidar HB. Release kinetics from bio-polymeric nanoparticles encapsulating protein synthesis inhibitor, cycloheximide, for possible therapeutic application. Curr Pharm Biotechnol 2005; 6:121-130. (Pubitemid 40637385)
24. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release 2006; 110:422-430. (Pubitemid 41827496)
25. Dewar MJS, Zoebisch EG, Healy EF, Stewart JJP. Development and use of quantum mechanics molecular models. 76. AM1: A new general purpose quantum mechanical molecular model. J Am Chem Soc 1985; 107: 3902-3909.
26. Gupta PK, Hung CT, Perrier DG. Quantitation of the release of doxorubicin from colloidal dosage forms using dynamic dialysis. J Pharm Sci 1987; 76:141-145. (Pubitemid 17043680)
27. Illum L, Davis SS. The targeting of drugs parenterally by use of microspheres. J Parenter Sci Technol 1982; 36:242-248. (Pubitemid 13202991)
28. Klimpel D, Cohon MS. pH of intravenous solutions. N Engl J Med 1969; 280:900-901.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63. (Pubitemid 14203433)
30. Huang M, Ma Z, Khor E, Lim LY. Uptake of FITC-chitosan nanoparticles by A549 cells. Pharm Res 2002; 19:1488-1494. (Pubitemid 35266553)
31. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14:1310-1316. (Pubitemid 351413909)
32. Frisch MJ, Trucks GW. Gaussian03 user's reference. Wallingford, CT: Gaussian Inc.; 2004.
33. Barone V, Cossi M. Quantum calculation of molecular energies and energy gradients in solution by a conductor solvent model. J Phys Chem A 1998; 102:1995-2001. (Pubitemid 128591338)
34. Cossi M, Rega N, Scalmani G, Barone V. Energies, structures, and electronic properties of molecules in solution with the C-PCM solvation model. J Comput Chem 2003; 24:669-681.
35. Kang KS, Morita I, Cruz A, Jeon YJ, Trosko JE, Chang CC. Expression of estrogen receptors in a normal human breast epithelial cell type with luminal and stem cell characteristics and its neoplastically transformed cell lines. Carcinogenesis 1997; 18:251-257. (Pubitemid 28132415)
36. Muvaffak A, Gurhan I, Hasirci N. Prolonged cytotoxic effect of colchicine released from biodegradable microspheres. J Biomed Mater Res B Appl Biomater 2004; 71:295-304. (Pubitemid 39463764)
37. Gupta AK, Gupta M, Yarwood SJ, Curtis AS. Effect of cellular uptake of gelatin nanoparticles on adhesion, morphology and cytoskeleton organization of human fibroblasts. J Control Release 2004; 95: 197-207. (Pubitemid 38230035)
38. Vandervoort J, Ludwig A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm 2004; 57:251-261. (Pubitemid 38283701)
39. Mohanty B, Bohidar HB. Microscopic structure of gelatin coacervates. Int J Biol Macromol 2005; 36:39-46. (Pubitemid 40966953)
40. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Res 1996; 56:1194-1198. (Pubitemid 26080953)
41. Weigel RJ, deConinck EC. Transcriptional control of estrogen receptor in estrogen receptor negative breast carcinoma. Cancer Res 1993; 53:3472-3474. (Pubitemid 23229622).